# Molecular Templates

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-templates

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.mtem.com
- Total disclosed funding: $18M
- Latest round: Series D (Dec 29, 2015)
- Investors on record: 3

## About

Based in the US, Molecular Templates, Inc. is a biopharmaceutical company focused on developing therapeutic solutions through engineered toxin bodies for targeted cancer treatment.Molecular Templates, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating therapeutic solutions for oncology. Established in 2001, the company is headquartered in Austin, Texas. The CEO, Eric Poma, has a background in biopharmaceuticals and previously co-founded other ventures. The company has raised a total of USD 20.00 mn, with its most recent funding round being a PIPE on July 20, 2020, led by BVF Partners and including investors like Adage Capital Management and BB Biotech. The firm has completed 18 deals to date.Molecular Templates, Inc. focuses on engineered toxin bodies (ETBs), which aim to specifically target and destroy cancer cells while preserving healthy tissue. Their product pipeline includes multiple candidates in clinical trials designed to enhance treatment efficacy and safety for various cancer types, primarily serving healthcare providers in the US and select European regions.In the fiscal year 2022, Molecular Templates, Inc. achieved revenue of USD 19.75 mn and reported an EBITDA of USD 97.23 mn. The company’s revenue model is driven by partnerships with pharmaceutical companies and research institutions, incorporating milestone payments, research funding, and potential royalties from developed products.Molecular Templates, Inc. is strategizing for future growth by advancing its clinical product candidates and exploring new geographic markets. The funds from the recent PIPE deal will support these initiatives, including the development of new ETB therapies. The company aims to enhance its market presence in Europe while leveraging existing partnerships to expedite clinical advancements. The funding from July 2020, where they sold 3.6 million shares for USD 43 mn, will be pivotal in driving these objectives forward.

## Funding rounds

- Series D, Dec 29, 2015 — Sante Ventures
- Series C, Sep 15, 2014, $3.5M — AJU IB Investment
- Series C, Oct 8, 2013, $8.5M — Sante Ventures, Excel Venture Management
- Series B, Jan 7, 2012, $3.6M — Sante Ventures
- Series A, Mar 20, 2009, $2.5M — Sante Ventures

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A, Series B, Series C, Series D
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series C
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C